







VIRGINIA BIOTECHNOLOGY RESEARCH PARTNERSHIP AUTHORITY

REPORT ON AUDIT
FOR THE YEAR ENDED
JUNE 30, 2022

Auditor of Public Accounts Staci A. Henshaw, CPA

www.apa.virginia.gov (804) 225-3350



AUDIT SUMMARY

We have audited the basic financial statements of the Virginia Biotechnology Research Partnership Authority (the Authority) as of and for the year ended June 30, 2022, and issued our report thereon, dated January 19, 2023. Our report, included in the Authority's Annual Report, is available at the Auditor of Public Accounts' website at www.apa.virginia.gov. Our audit of the Authority for the year ended June 30, 2022, found:

- the financial statements are presented fairly, in all material respects;
- no internal control findings requiring management's attention; and
- no instances of noncompliance or other matters required to be reported under <u>Government Auditing Standards</u>.



Commonwealth of Virginia

Auditor of Public Accounts

P.O. Box 1295 Richmond, Virginia 23218

January 19, 2023

The Honorable Glenn Youngkin Governor of Virginia

Joint Legislative Audit and Review Commission

Board Members Virginia Biotechnology Research Partnership Authority Board

INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in <u>Government Auditing Standards</u>, issued by the Comptroller General of the United States, the financial statements of the Virginia Biotechnology Research Partnership Authority (the Authority) as of and for the year ended June 30, 2022, and the related notes to the financial statements, which collectively comprise the Authority's basic financial statements, and have issued our report thereon dated January 19, 2023. Our report includes a reference to other auditors who audited the financial statement of the component unit of the Authority, as described in our report on the Authority's financial statements. The other auditors did not audit the financial statements of the component unit in accordance with <u>Government Auditing Standards</u>, and accordingly, this report does not include reporting on internal control over financial reporting or compliance and other matters associated with the component unit of the Authority.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Authority's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Authority's internal control. Accordingly, we do not express an opinion on the effectiveness of the Authority's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Authority's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under <u>Government Auditing Standards</u>.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with <u>Government Auditing Standards</u> in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

We discussed this report with management at an exit conference held on January 30, 2023.

Staci A. Henshaw
AUDITOR OF PUBLIC ACCOUNTS

EMS/clj

VIRGINIA BIOTECHNOLOGY RESEARCH PARTNERSHIP AUTHORITY

As of June 30, 2022

BOARD OF DIRECTORS

Michael Rao, Ex-Officio and Chair

Vida Williams, Vice Chair

Ken Ampy
Eric Edwards
Art Espey
Charles Macfarlane
J. Robert Mooney

Caren Merrick, Ex-Officio Levar Stoney, Ex-Officio

> **Executive Director** Chandra Briggman

Officers to the Board
Sara Maddox, Assistant Secretary to the Board